Company Analysis
Sign in

Krystal Biotech, Inc. (KRYS)

Nasdaq: KRYS · Biological Products, (No Diagnostic Substances) · Pittsburgh, PA · filing with the SEC since 2017
Full chart Alerts Compare
Grade7.6
◀ Past 7.1● Present 9.0▶ Future 6.1
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

14 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Krystal Biotech, Inc.’s names, not what it holds today.

Patents granted
14
14 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 3 in 2024 and 3 in 2023
Applications published
31
4 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
Biotechnology1
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Krystal Biotech, Inc. its own name
US, as the owner printed on each patent
14 granted
22 published
Krystal Biotech, Inc. its own name
named as the applicant on its applications, in US
0 granted
9 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 22, 202512,364,775Viral vectors for cancer therapyPharmaceuticalsKrystal Biotech, Inc.
Oct 29, 202412,128,122Recombinant nucleic acids encoding cosmetic protein(s) for aestheticOrganic fine chemistryKrystal Biotech, Inc.
Mar 5, 202411,918,660Viral vectors for cancer therapyPharmaceuticalsKrystal Biotech, Inc.
Jan 9, 202411,865,148Methods of delivering transgenes to the eyePharmaceuticalsKrystal Biotech, Inc.
Oct 10, 202311,779,660Viral vectors for cancer therapyPharmaceuticalsKrystal Biotech, Inc.
Aug 8, 202311,717,547Compositions and methods for the treatment of autosomal recessive congenital ichthyosisBiotechnologyKrystal Biotech, Inc.
May 9, 202311,642,384Compositions and methods for the treatment of Netherton SyndromePharmaceuticalsKrystal Biotech, Inc.
Nov 30, 202111,185,564Compositions and methods for the treatment of wounds, disorders, and diseases of the skinPharmaceuticalsKrystal Biotech, Inc.
Nov 10, 202010,829,529Compositions and methods for delivering CFTR polypeptidesPharmaceuticalsKrystal Biotech, Inc.
Sep 29, 202010,786,438Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applicationsOrganic fine chemistryKrystal Biotech, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 4, 20252025/0277237Compositions and Methods for the Treatment of Congenital IchthyosesBiotechnologyKrystal Biotech, Inc.
Aug 14, 20252025/0255797Recombinant Nucleic Acids Encoding Cosmetic Protein(s) For Aesthetic ApplicationsOrganic fine chemistryKrystal Biotech, Inc.
Feb 20, 20252025/0059565Compositions and Methods for Gene Delivery to the Airways and/or LungsPharmaceuticalsKrystal Biotech, Inc.
Jan 2, 20252025/0001004Methods and Compositions for Treating Conditions Involving the EyePharmaceuticalsKrystal Biotech, Inc.
Dec 5, 20242024/0398994Viral Vectors for Cancer TherapyPharmaceuticalsKrystal Biotech, Inc.
Oct 17, 20242024/0342308Methods and Compositions for Treating Conditions Involving the EyePharmaceuticalsKrystal Biotech, Inc.
Dec 28, 20232023/0414686COMPOSITIONS AND METHODS FOR THE TREATMENT OF WOUNDS, DISORDERS, AND DISEASES OF THE SKINPharmaceuticalsKrystal Biotech, Inc.
Oct 26, 20232023/0338583VIRAL VECTORS FOR CANCER THERAPYPharmaceuticalsKrystal Biotech, Inc. · patent 12,364,775 granted from it
Oct 26, 20232023/0338444COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOSOMAL RECESSIVE CONGENITAL ICHTHYOSISBiotechnologyKrystal Biotech, Inc.
Aug 3, 20232023/0241251VIRAL VECTORS FOR CANCER THERAPYPharmaceuticalsKrystal Biotech, Inc. · patent 11,918,660 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 4 · Organic fine chemistry 1 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton KRYS · research, not advice